{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6.47","upperLimit":"26.91","value":"18.96"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"}],"units":"Participants"}],"description":"The time from the start of treatment of MM patients treated with bendamustine, bortezomib and pegylated liposomal doxorubicin. to disease progression or death (regardless of cause of death), whichever comes first. Censoring date will be the last disease evaluation date.Per modified International Myeloma Working Group criteria: Progressive disease (PD) is reported if any one of the following criteria is met:\n\nIncrease of 25% or more in serum or urine M-protein from baseline;Serum M-protein and/or the absolute increase must be ≥0.5 g/dL;Urine M-protein and/or absolute increase must be ≥200 mg/24 hours ; Development of new bone lesions or soft tissue plasmacytomas or definite increase in the size of existing bone lesions or soft tissue plasmacytomas;Development of hyperc.","dispersionType":"95% Confidence Interval","groups":[{"description":"Bendamustine:\n\nAt phase II, Bendamustine will be administered at 90mg/m\\^2 by IV over 1 hour at days 1 and 4 of the 28 day treatment cycle.\n\nDoxorubicin:\n\nPegylated liposomal doxorubicin at phase II will be administered at 30 mg/m2 by IV over 1 hour,at day 4 of the 28 day treatment cycle.\n\nBortezomib:\n\nBortezomib at Phase II will be administered at 1.3 mg/m2 by IV bolus or SQ injection on days 1, 4, 8, and 11 of the 28 day cycle.","id":"OG000","title":"Phase II : Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin."}],"paramType":"MEDIAN","populationDescription":"Two subjects never received treatment. Therefore, they were not included in any assessment of objectives.","reportingStatus":"POSTED","timeFrame":"From C1D1 up to a maximum of 54 months until death","title":"Phase II: Progression-free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"months"}